Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology - 1 Oct 2009

Salgado María, Toro Carlos, Simón Ainhoa, Garrido Carolina, Blanco Francisco, Soriano Vincent, Rodés Berta

Abstract excerpt

BACKGROUND: Raltegravir has been shown to be active against wildtype HIV-2 with a phenotypic susceptibility similar to HIV-1. Due to the recent introduction of these novel inhibitors, information on the selection of resistance mutations and its phenotypic effect in this population is scarce. OBJECTIVES: To explore in vitro the effect of raltegravir resistance in one individual with HIV-2 infection who failed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Retroviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Integrase

Share to Pyrrolidinones

Share to Raltegravir Potassium

Share to Viral Load

Share to Virus Replication

Source

Identifiers

PMID: 19625211
DOI: 10.1016/j.jcv.2009.06.020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.PMID 19625211Read ↗

Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: implications for emerging HIV-2 treatment regimens.Semantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

Dolutegravir for the treatment of HIV-2 infection.Semantic proximity Read ↗

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy.Semantic proximity Read ↗

New dolutegravir resistance pattern identified in a patient failing antiretroviral therapySemantic proximity Read ↗

Spectrum of Activity of Raltegravir and Dolutegravir Against Novel Treatment-Associated Mutations in HIV-2 Integrase: A Phenotypic Analysis Using an Expanded Panel of Site-Directed Mutants.Semantic proximity Read ↗

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways.Semantic proximity Read ↗

HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen.Semantic proximity Read ↗

Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors.Semantic proximity Read ↗

Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.Semantic proximity Read ↗

Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.Semantic proximity Read ↗

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.